Amgen court case may heighten scrutiny of patent deals in pharmaceuticals — STAT News
A legal dispute between biotechnology company Amgen and a major health insurer has drawn attention to the conditions under which the acquisition of a patent application may allow a company to unfairly preserve a monopoly on a drug. As STAT News reports, the case is being watched for its potential impact on broader scrutiny of patent deals in the pharmaceutical industry.
Subject of the legal dispute
The case raises the question of where the line lies beyond which acquiring a patent application may become a way to unfairly preserve a monopoly on a drug. The publication notes that drugmakers are often accused of manipulating the US patent system to push out competitors.
Patent maneuvers are also sometimes described as one of the tools pharmaceutical companies may use to keep drug prices high. At the same time, STAT News does not claim that such actions by Amgen have already been proven in this dispute.
More current news is available on the UA.News Telegram channel Telegram.
FTC position
The US Federal Trade Commission unexpectedly sided with healthcare payers and consumers. According to the publication, the commission believes this mechanism deserves attention because of antitrust concerns.
The outcome of the proceedings could potentially lead to broader scrutiny of patent arrangements involving medicines.
